Intercellular adhesion molecule-1 expression in human endometrium: implications for long term progestin only contraception by unknown
BioMed Central
Reproductive Biology and 
Endocrinology
ssOpen AcceResearch
Intercellular adhesion molecule-1 expression in human 
endometrium: implications for long term progestin only 
contraception
Frederick Schatz1, Graciela Krikun1, Rebecca N Baergen2, 
Hilary OD Critchley3, Edward Kuczynski1 and Charles J Lockwood*1
Address: 1Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven CT, USA, 
2Department of Pathology, Weil-Cornell Medical Center, New York NY, USA and 3Centre for Reproductive Biology, University of Edinburgh, UK
Email: Frederick Schatz - frederick.schatz@yale.edu; Graciela Krikun - graciela.krikun@yale.edu; 
Rebecca N Baergen - rbaergen@med.cornell.edu; Hilary OD Critchley - hilary.critchley@ed.ac.uk; 
Edward Kuczynski - edward.kuczynski@yale.edu; Charles J Lockwood* - chairobgyn@yale.edu
* Corresponding author    
Abstract
Background: Neutrophils infiltrate the endometrium pre-menstrually and after long-term
progestin only-contraceptive (LTPOC) treatment. Trafficking of neutrophils involves endothelial
cell-expressed intercellular adhesion molecule (ICAM-1). Previous studies observed that ICAM-1
was immunolocalized to the endothelium of endometrial specimens across the menstrual cycle, but
disagreed as to whether extra-endothelial cell types express ICAM-1 and whether ICAM-1
expression varies across the menstrual cycle.
Methods: Endometrial biopsies were obtained from women across the menstrual cycle and from
those on LTPOC treatment (either Mirena or Norplant). The biopsies were formalin-fixed and
paraffin-embedded with subsequent immunohistochemical staining for ICAM-1.
Results: The current study found prominent ICAM-1 staining in the endometrial endothelium that
was of equivalent intensity in different blood vessel types irrespective of the steroidal or
inflammatory endometrial milieu across the menstrual cycle and during LTPOC therapy. Unlike the
endothelial cells, the glands were negative and the stromal cells were weakly positive for ICAM
immunostaining.
Conclusion: The results of the current study suggest that altered expression of ICAM-1 by
endothelial cells does not account for the influx of neutrophils into the premenstrual and LTPOC-
derived endometrium. Such neutrophil infiltration may depend on altered expression of neutrophil
chemoattractants.
Background
The premenstrual human endometrium displays
increased prostaglandin-generating capacity, elevated lev-
els of inflammatory cytokines [1,2] and a leukocyte infil-
trate that comprises nearly one-half of the cell population
[3-5]. Among endometrial leukocyte subtypes, neu-
trophils are virtually absent until the mid-luteal phase,
but comprise a significant portion of the leukocytes in the
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traceptive (LTPOC) administration, the endometrium
also experiences enhanced prostaglandin-generating
capacity and increased inflammatory cytokine levels [6,7].
Administration of Norplant, which releases levonorgestrel
(LNG) from subdermal rods, and Mirena, which releases
LNG from an intrauterine system, leads to endometrial
infiltration of matrix metalloproteinase-9 (MMP-9) posi-
tive neutrophils [8], and macrophages [9], respectively.
Endothelial cell-expressed cellular adhesion molecules
mediate leukocyte trafficking [10]. In this regard, particu-
lar attention has been directed at the physiological and
pathological roles played by intercellular adhesion mole-
cule (ICAM-1), a 76-114-kDa surface glycoprotein that
has five extracellular immunoglobulin-like domains [11-
14].Transmigration of leukocytes involves high-affinity
binding of LFA-1 or Mac-1 on their surface to ICAM-1
expressed on the endothelium [10]. ICAM-1 deficient
mice experience numerous inflammatory response abnor-
malities including impaired neutrophil trafficking
[15,16]. Although ICAM-1 has been immunolocalized to
the endothelium of various blood vessel types in speci-
mens of cycling endometrium, there are conflicting
reports as to whether extra-endothelial cell types also
express ICAM-1, and whether ICAM-1 expression varies
across the menstrual cycle [17-19]. In view of this lack of
consensus, the current study reassessed immunohisto-
chemical (IHC) staining for ICAM-1 in endometrial biop-
sies across the menstrual cycle, and extended the use of
IHC staining of ICAM-1 to include endometrial tissues
exposed to subdermal (Norplant) and intra-uterine
(Mirena, Schering) exogenous progestogens. Both LTPOC
types provide safe and effective contraception for several
years. Norplant is particularly well suited for use in under-
developed countries where access to trained medical per-
sonnel is limited. They are discontinued primarily
because of inflammation-associated abnormal uterine
bleeding (AUB) as a source of personal annoyance and
discomfort as well as cultural and religious taboo [20,21].
The levonorgestrel-releasing intra-uterine system (LNG-
IUS, Mirena) is now increasingly used as an effective con-
traceptive and for its associated health benefits, including
reduction in menstrual blood loss [22].
Prior to menstruation and during progestin-only contra-
ception (Norplant, Mirena), secretion of MMPs by
endometrial leukocytes as well as cytokines that can act as
autocrine/paracrine modulators of MMP expression [5],
are thought to enhance degradation of the vascular sup-
port structure leading to stromal collapse and bleeding
[23-26]. The current study sought to determine whether
altered expression of ICAM-1 could account for infiltra-




After receiving written informed consent and approval
from the Institutional Research Board (IRB) of New York
University Medical Center and Bellevue Hospital, speci-
mens of endometrium were obtained across the men-
strual cycle (four each from the follicular and luteal
phases and five from the menstrual phase) from hysterec-
tomies for benign conditions (e.g. myomas without
abnormal uterine bleeding), and histologically dated by
the criteria of Noyes et al [27]. For studies on LTPOC-
derived endometrium, institutional ethical review and
approval was obtained from the New York University IRB
and the Lothian Research Ethical Committee, Scotland
and written informed consent was obtained for biopsy
collection.
The subjects had regular menstrual cycles and had not
used hormonal or intrauterine contraception in the six
months prior to insertion of Norplant or Mirena. Patients
did not exhibit symptoms characteristic of endometriosis
such as pelvic pain, dysmennorhea, dysparunia, or infer-
tility. The only way to confirm a diagnosis of endometrio-
sis is through exploratory surgery. Such surgery would be
prompted by symptoms that would have ruled out the use
of those patients for our study. For the cycling
endometrium patients were pre-menopausal between 32
and 43 years of age who were not receiving any hormonal
treatments. For the LTPOC endometrium patients were
premenopausal, between 28 and 45 years of age, had reg-
ular menstrual cycles and had not used any hormonal or
intrauterine contraception in the six months prior to
receiving the LTPOC treatment.
Norplant specimens
Prior to insertion of Norplant biopsies were collected
from four women (two in the follicular and two in the
luteal phase) by Pipelle suction curette (Laboratoire CCD,
Paris, France). Only patients who experienced bleeding
while on the Norplant treatment were used. Biopsies were
collected using an operative hysteroscope connected to a
video camera to facilitate separate sampling of bleeding
and non-bleeding sites as previously described [25]. These
samples were taken after 3 and 12 months post Norplant
insertion.
Mirena specimens
Endometrial biopsies were also obtained from four
women (two in the follicular and two in the luteal phase)
prior to and at 1, 3, 6, and 12 months after intrauterine
insertion of the LNG-intrauterine system by Pipelle suc-
tion biopsy.Page 2 of 7
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Specimens of endometrium obtained across the men-
strual cycle as well as from control, and levonorgestrel
treated (Norplant, Mirena) subjects were fixed in 4% para-
formaldehyde and embedded in paraffin. Four µm sec-
tions (4 µm) were deparaffinized, rehydrated and washed
in Tris-buffered saline [TBS: 20 mmol/l Tris-HCl, 150
mmol/l NaCl (pH 7.6)], which was used for all washes
and for dilution of the antibody. Antigen retrieval was car-
ried-out by incubating sections in sodium citrate buffer
(10 mM, pH 6.0) in a microwave oven at 750 Watts for 5
minutes. The sections were then rinsed in 3% hydrogen
peroxide to block endogenous peroxidase and incubated
for 1 hour at room temperature with either of the follow-
ing primary antibodies: a goat polycolonal ICAM-1
(CD54) antibody from R&D Systems (R&D Systems, Inc.,
Minneapolis, MN) or a monoclonal antibody against the
Platelet Adhesion Molecule (PECAM) (CD31) from Dako
(DakoCytomation California, Inc., Carpinteria, CA).
Staining was visualized using the avidin-biotin peroxidase
complex (Vectastain ABC kit, Vector Laboratories, Burlin-
game, CA) and the 3,3'-diaminobenzidine tetrahydro-
chloride (Sigma-Aldrich, St. Louis, MI) chromogen
substrate. Light hematoxylin stain was used for nuclear
counterstaining. Negative controls for each tissue section
consisted of substituting the corresponding pre-immune
serum for the primary antibody.
Assessment of immunohistochemical (IHC) staining and 
statistical analysis
Intensity of ICAM-1 staining was evaluated using a semi-
quantitative 4-point rating method with the following
scoring system: 0, absence of staining; 1, light staining; 2
moderate staining; and 3, strong staining. Each of these
possible scores was established in advance of rating the
fields via reference to external stained specimens unre-
lated to this study. In order to determine inter-rater relia-
bility of this scale, two independent judges scored a series
of 35 separate fields on slides from 4 separate patient sam-
ples. The degree of concordance was then assessed by use
of Cohen's kappa statistic, which yielded a value of 0.67,
indicating a high degree of agreement between the judges.
Non-parametric statistical analysis was performed by the
Mann-Whitney Rank Sum Test with p < 0.05 considered
significant.
Results
Figure 1 (C-F) displays IHC staining for ICAM-1 in
endometrial specimens obtained across the menstrual
cycle. As expected, there was a lack of staining in the neg-
ative control (A). The endothelium of all specimens exam-
ined stained prominently, displaying an intensity that
appeared to be independent of hormonal or inflamma-
tory state. Thus, staining intensity did not vary signifi-
cantly among specimens obtained from the estrogen-
regulated follicular phase (C), the progestin-dominated
luteal phase (D), or from the pro-inflammatory milieu
characteristic of the ovarian steroid withdrawal-initiated
menstrual phase (E-F). In both intensity and specificity for
the endothelium, immunostaining for ICAM-1 was simi-
lar to that of CD31 (shown in Figure 1B), a documented
endothelial cell marker whose expression was demon-
strated by Tawia [18] to be essentially unchanged across
the menstrual cycle. The "stromal ball" displayed by the
specimen of menstrual endometrium in (F) indicates that
in contrast with the intense IHC staining for ICAM-1
exhibited by the endothelium of the compressed vessels,
Immunostaining for ICAM-1 and CD 31 in human endometrium during the menstrual cycleFigure 1
Immunostaining for ICAM-1 and CD 31 in human 
endometrium during the menstrual cycle.Negative 
control for menstrual endometrium (A). Prominent ICAM-1 
staining is evident in the endothelium in endometrial speci-
mens from the follicular phase (C), luteal phase (D), and 
menstrual phase (E, F). Similar endothelial cell staining inten-
sity and specificity for CD 31 is seen in the menstrual speci-
men shown in (B). The prominent structure in the menstrual 
specimen shown in (F) is a "stromal ball," which results from 
degenerative changes of the stroma. Note the compressed 
blood vessels displaying prominent immunostaining for 
ICAM-1, whereas the surrounding stromal cells were only 
weakly positive. Arrow = blood vessel; g = gland. Bar = 50 
µm.Page 3 of 7
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tive immunoreactivity. This observation contradicts a
report that stromal cells of cycling human endometrium
display significant ICAM-1 IHC staining whose intensity
peaks during the menstrual phase [18].
Figure 2 displays IHC staining for ICAM-1 in endometrial
specimens obtained after administration of the LTPOCs,
Norplant (B-E) and Mirena (F-I). As observed in Figure 1
for endometria obtained across the menstrual cycle, Fig-
ure 2 demonstrates that imunoreactive ICAM-1 was also
localized specifically to the endothelium of LTPOC-
derived endometrium with staining intensity that was
equivalent among various vessel types and independent
of both steroidal and inflammatory state. Thus, consistent
with direct delivery of LNG to the uterus with Mirena con-
traception the progestin-induced decidualization reaction
in these specimens (F-I) is much greater than in Norplant-
derived specimens (B-E). Moreover, despite the docu-
mented increase in pro-inflammatory cytokines [6,7] and
leukocyte infiltration [8,9] during LTPOC-induced abnor-
mal uterine bleeding, no differences in endothelial cell
IHC staining for ICAM-1 were evident whether the
endometrium exhibited abnormal uterine bleeding or
gave no indication of bleeding. Specifically, with Nor-
plant administration this comparison was between bleed-
ing (C, E) and non-bleeding sites (B, D) of the same
endometrium. With Mirena administration comparisons
are between patients experiencing abnormal uterine
bleeding G, I) and those who were not bleeding (F, H).
For both figures, our rating of staining intensity was char-
acterized by good inter-rater reliability, with a Cohen's
kappa value of 0.67 for observations made by two inde-
pendent observers (See Methods for details).
Discussion
The current study found that human endometrial
endothelial cells displayed prominent IHC staining for
ICAM-1 in specimens obtained from the follicular, luteal
and menstrual phases, and after administration of the
LTPOCs, Norplant (subdermal LNG) and Mirena (intrau-
terine LNG) and that this staining was of equivalent inten-
sity in all vessels examined. By contrast, the glands
exhibited virtually no immunostaining and the stromal
cells only weak immunoreactivity. Although IHC staining
for ICAM-1 was previously demonstrated in the endome-
trial endothelium of specimens obtained across the men-
strual cycle [17-19], two of the reports found significant
ICAM-1 staining in the stromal cells [18,19], with one
study noting that ICAM-1 levels in both stromal cells and
endothelial cells were elevated in menstrual
endometrium compared with specimens examined earlier
in the menstrual cycle [18].
Immunostaining for ICAM-1 in human endometrium during long term o ly contraceptive (LTPOC) a ministrationFigur  2
Immunostaining for ICAM-1 in human endometrium 
during long term only contraceptive (LTPOC) 
administration. IHC staining in the endothelium was prom-
inent and specific for the endothelium in in all endometrial 
specimens examined. Samples obtained from women using 
Norplant (subdermal LNG) (B-E)-: (B) 3 months post-Nor-
plant non-bleeding site; (C) 3 months post-Norplant, bleed-
ing site; (D) 12 months post-Norplant, non-bleeding site; and 
(E) 12 months post Norplant, bleeding site. Similar results 
were seen in endometrial specimens from women using 
Mirena (intrauterine LNG) (F-I):-;(F) 3 months post-Mirena, 
non-bleeding (F); 3 months post-Mirena, bleeding; (G) 12 
months post-Mirena, non-bleeding; and (I) 12 months post-
Mirena, bleeding. Note that the stromal cells exhibit a much 
greater decidualization reaction following intrauterine admin-
istration of LNG (F-I) than after subdermal LNG (B-E). 
Arrow = blood vessel; g = gland; DC = decidualized stromal 
cell. Bar = 50 µm.Page 4 of 7
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are equivalent in the endometrial endothelium of speci-
mens from the E2-dominated follicular phase, the proges-
terone-exposed luteal phase, and the steroid-withdrawal-
initiated menstrual phase suggests that ICAM-1 expres-
sion is not under direct ovarian steroid regulation. This
conclusion was supported by the ICAM-1 immunostain-
ing results obtained in endometrial biopsies during use of
subdermal and intrauterine LNG (Norplant and Mirena
respectively) contraception. That both LTPOCs produce a
hyperprogestational endometrial milieu is suggested by
the observation of significantly high endometrial levels of
the progesterone receptor (PR) isoforms PRA and PRB after
administration of Norplant [24] as well as the injectable
LTPOC, Provera [23], whereas PRA appears to mediate the
long-term effects of LNG in the endometrium during
intrauterine LNG contraception [6]. Endometrial levels of
LNG that are 1000 times greater with intrauterine delivery
(Mirena) than with subdermal LNG administration (Nor-
plant) [28]. However, the current study observed no dif-
ference in endometrial endothelial ICAM-1
immunostaining regardless of which LNG formulation
was evaluated.
Evidence presented in the current study also argues
against a role for the local inflammatory milieu in regulat-
ing endothelial cell expressed ICAM-1. Thus, equivalent
immunostaining intensity was observed when follicular
and luteal phase endometria were compared with men-
strual, Norplant, and Mirena-derived endometria, which
undergo a marked leukocyte infiltration [3-5,8,9] and
exhibit other local pro-inflammatory changes such as a
high prostaglandin-generating capacity and elevated
interleukin-8 (IL-8) levels [1,2,6,7].
ICAM-1 is both constitutively expressed and transcrip-
tionally regulated on the surface of several cell types [29].
Consistent with the latter, the ICAM-1 gene promoter con-
tains several cis-acting elements that predict responsive-
ness to pro-inflammatory cytokines and reactive oxygen
species (ROS). Cooperativity between transcription fac-
tors C/EBP and NfκB mediate tumor necrosis factor alpha
(TNF-α) and interleukin 1beta (IL-1β) responses. Actions
of H2O2 are mediated by antioxidant response elements
(ARE), which bind transcription factors AP-1 and Ets [29].
As expected, TNF-α, whose pro-inflammatory activity
requires ROS formation, induces ICAM-1 expression in
endothelial and epithelial cells and H2O2 induces ICAM-
1 expression in endothelial cells. However, H2O2 does
not affect ICAM-1 expression in epithelial cells [30].
In vivo studies have generally relied on IHC to localize
and assess ICAM-1 levels. Table 1 summarizes the results
of nine previous reports, three in nonpregnant
endometrium [17-19] and six in pregnant endometrium
(decidua) [31-36]. The majority of these agree with the
Table 1: Previously reported ICAM-1 immunostaining in non-pregnant and gestational endometrium. FT: first trimester; FF-PE: 
formalin-fixed, paraffin-embedded; PE: pre-eclampsia, IUGR: intrauterine growth retardation
Reference Tissue type Tissue Preparation Endothelial Cell ICAM-
1 staining
Non-endothelial Cell ICAM-1 
staining
17 Cycling endometrium Frozen (formalin-fix) Strong, constitutive Uniform staining of glands, stroma, and 
epithelium; strong lymphoid staining
18 Cycling endometrium Frozen (formalin-fix) Strong but variable among 
vessel types with peak at 
menstrual
Glandular and luminal epithelium 
negative, stroma weak in proliferative/
secretory phases but strong at 
menstrual
19 Cycling endometrium Frozen (acetone-fix) and 
FF-PE
Strong throughout entire 
cycle
Glandular and luminal epithelium 
variable, stroma stained throughout 
cycle with increase expression in 
menstrual; widespread lymphoid 
staining
31 FT Decidua Frozen (acetone-fix) Strong in all vessel types Glands negative, stroma weak, 
moderate staining of lymphocytes
32 FT Decidua, placenta Frozen (acetone-fix) Strong in all vessel types Stroma negative, strong lymphocyte 
staining, strong staining of decidua 
parietalis,
33 FT decidua Frozen (acetone-fix) Strong in all vessel types Glands negative, some stroma positive
34 Decidua, placental bed Frozen (acetone-fix) Strong, unchanged in 
normal vs. PE, IUGR, or 
PE+IUGR
Weak scattered stromal cell staining
35 Decidua, placenta Frozen (acetone-fix) Strong, unchanged in 
normal vs. PE
Villous trophoblasts negative, <10% 
interstitial trophoblasts stained
36 FT decidua FF-PE Strong in all vessel types, 
same in normal vs. 
inflammation; constitutive
Glands negative, stroma weakPage 5 of 7
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taining in a variety of blood vessel types that appears to be
constitutive even in a pro-inflammatory milieu. Recently,
in first trimester from cases of hemorrhagic, acutely
inflamed, regressing deciduas, we found that endothelial
cell ICAM-1 staining intensity was unaffected by the prox-
imity of blood vessels to cytokine-expressing neutrophils
[36]. Moreover, despite reports that preeclamptic decidua
display a marked macrophage infiltrate and high levels of
TNF-α, [37,38] other reports [34,35] found that endothe-
lial cell ICAM-1 expression was similar in decidua from
preeclamptic or gestationally age-matched placentas.
These studies agree with observations made in the current
study for nonpregnant endometrium. It found equivalent
ICAM-1 immmunostaining intensity in the endothelium
of follicular and luteal phase endometria compared with
menstrual, Norplant and Mirena-derived endometria,
which exhibit such local pro-inflammatory changes as a
marked leukocyte infiltrate [3-5,8,9], high prostaglandin-
generating capacity and elevated interleukin-8 (IL-8) lev-
els [1,2,6,7].
Regulation of neutrophil migration into inflammatory
sites reflects interactions between the IL-8 chemokine and
the ICAM-1 adhesion molecule. The former establishes a
chemotactic gradient that promotes neutrophil trafficking
from the circulation towards the endothelium [39]. This
enables the latter to mediate neutrophil rolling and adhe-
sion prior to transendothelial migration [40]. Neutrophils
are rich source of gelatinase B (MMP-9) [41], which
degrades basement membrane associated collagens IV
and V [42]. Moreover, neutrophil-derived MMP-9 cleaves
IL-8 to a truncated form [IL-8(7-77)] with 10–30- fold
greater potency in promoting neutrophil activation and
chemotaxis [41]. The onset of AUB during LTPOC admin-
istration stems from fragile, abnormally distended vessels
with impaired basement membranes"[43,44]. Adminis-
tration of LTPOCs produces local hypoxia stemming from
reduced uterine vasomotion (45), and increases stromal
cell expression of tissue factor, which can generate
thrombin at local sites of AUB [46]. The demonstration in
the current study that ICAM-1 is constitutively expressed
by the endometrial endothelium highlights the important
role that altered IL-8 expression plays in regulating neu-
trophil trafficking into the endometrium. Toward that
end, we recently demonstrated that IL-8 expression is
enhanced by hypoxia and thrombin in stromal cells
derived from pre-decidualized human endometrium [47].
Conclusion
In the context of our current observations, constitutive
endothelial ICAM-1 expression alone cannot account for
the marked neutrophil infiltration that characterizes both
premenstrual human endometrium as well as the
endometrium resulting from LTPOC therapy.
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